Competitive interaction between fibroblast growth factor 23 and asymmetric dimethylarginine in patients with CKD

Journal of the American Society of Nephrology

Volumn 26, Issue 4, 2015, Pages 935-944

  Tripepi, Giovanni ^a   Kollerits, Barbara ^b   Leonardis, Daniela ^a   Yilmaz, Mahamut Ilker ^c   Postorino, Maurizio ^a,d   Fliser, Danilo ^e   Mallamaci, Francesca ^a,d   Kronenberg, Florian ^b   Zoccali, Carmine ^a,d  

^a Institute of Clinical Physiology (IFC) Institute of Biomedicine and Molecular Immunology (IBIM) Research Unit   (Italy)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c GULHANE SCHOOL OF MEDICINE   (Turkey)

^d BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

^e SAARLAND UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

6 N,N' DIMETHYLARGININE; ALBUMIN; ANTIHYPERTENSIVE AGENT; CALCIUM; FIBROBLAST GROWTH FACTOR 23; HEMOGLOBIN; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE; PARATHYROID HORMONE; PHOSPHATE; TRIACYLGLYCEROL; ARGININE; FIBROBLAST GROWTH FACTOR; N,N-DIMETHYLARGININE;

ADULT; ARTICLE; CARBOXY TERMINAL SEQUENCE; CENTRAL EUROPEAN; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; DISEASE COURSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PHOSPHATE METABOLISM; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN INTERACTION; PROTEIN MODIFICATION; PROTEIN URINE LEVEL; PROTEINURIA; SOUTHERN EUROPE; TRIACYLGLYCEROL BLOOD LEVEL; AGED; ANALOGS AND DERIVATIVES; BLOOD; ITALY; MIDDLE AGED; RENAL INSUFFICIENCY, CHRONIC;

ADULT; AGED; ARGININE; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; ITALY; MALE; MIDDLE AGED; RENAL INSUFFICIENCY, CHRONIC;

EID: 84926500202     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2013121355     Document Type: Article

References (48)

1. Quarles LD: Endocrine functions of bone in mineral metabolism regulation. J Clin Invest 118: 3820-3828, 2008
2. Hu MC, Shiizaki K, Kuro-o M, Moe OW: Fibroblast growth factor 23 and Klotho: physiology and pathophysiology of an endocrine network of mineral metabolism. Annu Rev Physiol 75: 503-533, 2013
3. Gutiérrez OM, Wolf M, Taylor EN: Fibroblast growth factor 23, cardiovascular disease risk factors, and phosphorus intake in the health professionals follow-up study. Clin J Am Soc Nephrol 6: 2871-2878, 2011
4. Mirza MA, Alsiö J, Hammarstedt A, Erben RG, Michaëlsson K, Tivesten A, Marsell R, Orwoll E, Karlsson MK, Ljunggren O, Mellström D, Lind L, Ohlsson C, Larsson TE: Circulating fibroblast growth factor-23 is associated with fat mass and dyslipidemia in two independent cohorts of elderly individuals. Arterioscler Thromb Vasc Biol 31: 219-227, 2011
5. Wolf M: Update on fibroblast growth factor 23 in chronic kidney disease. Kidney Int 82: 737-747, 2012
6. Isakova T, Wahl P, Vargas GS, Gutiérrez OM, Scialla J, Xie H, Appleby D, Nessel L, Bellovich K, Chen J, Hamm L, Gadegbeku C, Horwitz E, Townsend RR, Anderson CA, Lash JP, Hsu CY, Leonard MB, Wolf M: Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 79: 1370-1378, 2011
7. Gutiérrez OM: Fibroblast growth factor 23 and disordered vitamin D metabolism in chronic kidney disease: Updating the "trade-off" hypothesis. Clin J Am Soc Nephrol 5: 1710-1716, 2010
8. Dai B, David V, Martin A, Huang J, Li H, Jiao Y, Gu W, Quarles LD: A comparative transcriptome analysis identifying FGF23 regulated genes in the kidney of a mouse CKD model. PLoS ONE 7: e44161, 2012
9. Zanchi C, Locatelli M, Benigni A, Corna D, Tomasoni S, Rottoli D, Gaspari F, Remuzzi G, Zoja C: Renal expression of FGF23 in progressive renal disease of diabetes and the effect of ACE inhibitor. PLoS ONE 8: e70775, 2013
10. Fliser D, Kollerits B, Neyer U, Ankerst DP, Lhotta K, Lingenhel A, Ritz E, Kronenberg F, Kuen E, König P, Kraatz G, Mann JF, Müller GA, Köhler H, Riegler P; MMKD Study Group: Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: The Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol 18: 2600-2608, 2007
11. Isakova T, Xie H, Yang W, Xie D, Anderson AH, Scialla J, Wahl P, Gutiérrez OM, Steigerwalt S, He J, Schwartz S, Lo J, Ojo A, Sondheimer J, Hsu CY, Lash J, Leonard M, Kusek JW, Feldman HI, Wolf M; Chronic Renal Insufficiency Cohort (CRIC) Study Group: Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 305: 2432-2439, 2011
12. Kendrick J, Cheung AK, Kaufman JS, Greene T, Roberts WL, Smits G, Chonchol M; HOST Investigators: FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis. J Am Soc Nephrol 22: 1913-1922, 2011
13. Semba RD, Fink JC, Sun K, Cappola AR, Dalal M, Crasto C, Ferrucci L, Fried LP: Serum fibroblast growth factor-23 and risk of incident chronic kidney disease in older community-dwelling women. Clin J Am Soc Nephrol 7: 85-91, 2012
14. Scialla JJ, Astor BC, Isakova T, Xie H, Appel LJ, Wolf M: Mineral metabolites and CKD progression in African Americans. J Am Soc Nephrol 24: 125-135, 2013
15. Wolf M, Molnar MZ, Amaral AP, Czira ME, Rudas A, Ujszaszi A, Kiss I, Rosivall L, Kosa J, Lakatos P, Kovesdy CP, Mucsi I: Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality. J Am Soc Nephrol 22: 956-966, 2011
16. Kielstein JT, Impraim B, Simmel S, Bode-Böger SM, Tsikas D, Frölich JC, Hoeper MM, Haller H, Fliser D: Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginine in humans. Circulation 109: 172-177, 2004
17. Kielstein JT, Simmel S, Bode-Böger SM, Roth HJ, Schmidt-Gayk H, Haller H, Fliser D: Subpressor dose asymmetric dimethylarginine modulates renal function in humans through nitric oxide synthase inhibition. Kidney Blood Press Res 27: 143-147, 2004
18. Yilmaz MI, Saglam M, Caglar K, Cakir E, Sonmez A, Ozgurtas T, Aydin A, Eyileten T, Ozcan O, Acikel C, Tasar M, Genctoy G, Erbil K, Vural A, Zoccali C: The determinants of endothelial dysfunction in CKD: oxidative stress and asymmetric dimethylarginine. Am J Kidney Dis 47: 42-50, 2006
19. Bai Y, Sun L, Du L, Zhang T, Xin W, Lan X, Du G: Association of circulating levels of asymmetric dimethylarginine (ADMA) with carotid intimamedia thickness: Evidence from 6168 participants. Ageing Res Rev 12: 699-707, 2013
20. Ravani P, Tripepi G, Malberti F, Testa S, Mallamaci F, Zoccali C: Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risks modeling approach. J Am Soc Nephrol 16: 2449-2455, 2005
21. Fliser D, Kronenberg F, Kielstein JT, Morath C, Bode-Böger SM, Haller H, Ritz E: Asymmetric dimethylarginine and progression of chronic kidney disease: The mild to moderate kidney disease study. J Am Soc Nephrol 16: 2456-2461, 2005
22. Hanai K, Babazono T, Nyumura I, Toya K, Tanaka N, Tanaka M, Ishii A, Iwamoto Y: Asymmetric dimethylarginine is closely associated with the development and progression of nephropathy in patients with type 2 diabetes. Nephrol Dial Transplant 24: 1884-1888, 2009
23. Lajer M, Tarnow L, Jorsal A, Teerlink T, Parving HH, Rossing P: Plasma concentration of asymmetric dimethylarginine (ADMA) predicts cardiovascular morbidity and mortality in type 1 diabetic patients with diabetic nephropathy. Diabetes Care 31: 747-752, 2008
24. Mihout F, Shweke N, Bigé N, Jouanneau C, Dussaule JC, Ronco P, Chatziantoniou C, Boffa JJ: Asymmetric dimethylarginine (ADMA) induces chronic kidney disease through a mechanism involving collagen and TGF-β1 synthesis. J Pathol 223: 37-45, 2011
25. Mirza MA, Larsson A, Lind L, Larsson TE: Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the community. Atherosclerosis 205: 385-390, 2009
26. Yilmaz MI, Sonmez A, Saglam M, Yaman H, Kilic S, Demirkaya E, Eyileten T, Caglar K, Oguz Y, Vural A, Yenicesu M, Zoccali C: FGF-23 and vascular dysfunction in patients with stage 3 and 4 chronic kidney disease. Kidney Int 78: 679-685, 2010
27. Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T, Gutiérrez OM, Aguillon-Prada R, Lincoln J, Hare JM, Mundel P, Morales A, Scialla J, Fischer M, Soliman EZ, Chen J, Go AS, Rosas SE, Nessel L, Townsend RR, Feldman HI, St John Sutton M, Ojo A, Gadegbeku C, Di Marco GS, Reuter S, Kentrup D, Tiemann K, Brand M, Hill JA, Moe OW, Kuro-OM, Kusek JW, Keane MG, Wolf M: FGF23 induces left ventricular hypertrophy. J Clin Invest 121: 4393-4408, 2011
28. Mucsi I, Ujszaszi A, Wolf MS, Kielstein JT, Molnar MZ: Serum FGF23 levels are indepently associated with serum asymmetric dimethylarginine (ADMA) levels in kidney transplant recipients. [Abstract] J Am Soc Nephrol 23: 803A, 2012
29. Kang DH, Kanellis J, Hugo C, Truong L, Anderson S, Kerjaschki D, Schreiner GF, Johnson RJ: Role of the microvascular endothelium in progressive renal disease. J Am Soc Nephrol 13: 806-816, 2002
30. Yilmaz MI, Stenvinkel P, Sonmez A, Saglam M, Yaman H, Kilic S, Eyileten T, Caglar K, Oguz Y, Vural A, Çakar M, Altun B, Yenicesu M, Carrero JJ: Vascular health, systemic inflammation and progressive reduction in kidney function; clinical determinants and impact on cardiovascular outcomes. Nephrol Dial Transplant 26: 3537-3543, 2011
31. Shuto E, Taketani Y, Tanaka R, Harada N, Isshiki M, Sato M, Nashiki K, Amo K, Yamamoto H, Higashi Y, Nakaya Y, Takeda E: Dietary phosphorus acutely impairs endothelial function. J Am Soc Nephrol 20: 1504-1512, 2009
32. Zoccali C: Asymmetric dimethylarginine (ADMA): A cardiovascular and renal risk factor on the move. J Hypertens 24: 611-619, 2006
33. Leiper JM: The DDAH-ADMA-NOS pathway. Ther Drug Monit 27: 744-746, 2005
34. Cardounel AJ, Cui H, Samouilov A, Johnson W, Kearns P, Tsai AL, Berka V, Zweier JL: Evidence for the pathophysiological role of endogenous methylarginines in regulation of endothelial NO production and vascular function. J Biol Chem 282: 879-887, 2007
35. Saito Y, Yamagishi T, Nakamura T, Ohyama Y, Aizawa H, Suga T, Matsumura Y, Masuda H, Kurabayashi M, Kuro-o M, Nabeshima Y, Nagai R: Klotho protein protects against endothelial dysfunction. Biochem Biophys Res Commun 248: 324-329, 1998
36. Nakamura T, Saito Y, Ohyama Y, Masuda H, Sumino H, Kuro-o M, Nabeshima Y, Nagai R, Kurabayashi M: Production of nitric oxide, but not prostacyclin, is reduced in klotho mice. Jpn J Pharmacol 89: 149-156, 2002
37. Olauson H, Lindberg K, Amin R, Jia T, Wernerson A, Andersson G, Larsson TE: Targeted deletion of Klotho in kidney distal tubule disrupts mineral metabolism. J Am Soc Nephrol 23: 1641-1651, 2012
38. Baylis C, Qiu C: Importance of nitric oxide in the control of renal hemodynamics. Kidney Int 49: 1727-1731, 1996
39. Bidani AK, Polichnowski AJ, Loutzenhiser R, Griffin KA: Renal microvascular dysfunction, hypertension and CKD progression. Curr Opin Nephrol Hypertens 22: 1-9, 2013
40. Zoccali C, Leonardis D, Enia G, Postorino M, Mallamaci F; MAURO study working group: The MAURO study: Multiple intervention and audit in renal diseases to optimize care. J Nephrol 21: 20-22, 2008
41. Leonardis D, Mallamaci F, Enia G, Postorino M, Tripepi G, Zoccali C; MAURO Study Investigators: The MAURO study: Baseline characteristics and compliance with guidelines targets. J Nephrol 25: 1081-1090, 2012
42. Schulze F, Wesemann R, Schwedhelm E, Sydow K, Albsmeier J, Cooke JP, Böger RH: Determination of asymmetric dimethylarginine (ADMA) using a novel ELISA assay. Clin Chem Lab Med 42: 1377-1383, 2004
43. Pecchini P, Malberti F, Mieth M, Quinn R, Tripepi G, Mallamaci F, Maas R, Zoccali C, Ravani P: Measuring asymmetric dimethylarginine (ADMA) in CKD: A comparison between enzyme-linked immunosorbent assay and liquid chromatography-electrospray tandem mass spectrometry. J Nephrol 25: 1016-1022, 2012
44. Martens-Lobenhoffer J, Bode-Böger SM: Simultaneous detection of arginine, asymmetric dimethylarginine, symmetric dimethylarginine and citrulline in human plasma and urine applying liquid chromatographymass spectrometry with very straightforward sample preparation. J Chromatogr B Analyt Technol Biomed Life Sci 798: 231-239, 2003
45. Bostom AG, Kronenberg F, Ritz E: Predictive performance of renal function equations for patients with chronic kidney disease and normal serum creatinine levels. J Am Soc Nephrol 13: 2140-2144, 2002
46. Grubbs FE: Procedures for detecting outlying observations in samples. Technometrics 11: 1:21, 1969
47. Jager KJ, Zoccali C, Macleod A, Dekker FW: Confounding: What it is and how to deal with it. Kidney Int 73: 256-260, 2008
48. Allignol A, Schumacher M, Wanner C, Drechsler C, Beyersmann J: Understanding competing risks: A simulation point of view. BMC Med Res Methodol 11: 86, 2011